GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Cyclically Adjusted Book per Share

Revance Therapeutics (STU:RTI) Cyclically Adjusted Book per Share : €4.32 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Revance Therapeutics's adjusted book value per share for the three months ended in Sep. 2024 was €-1.400. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.32 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Revance Therapeutics's average Cyclically Adjusted Book Growth Rate was -7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-29), Revance Therapeutics's current stock price is €3.44. Revance Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €4.32. Revance Therapeutics's Cyclically Adjusted PB Ratio of today is 0.80.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Revance Therapeutics was 6.89. The lowest was 0.48. And the median was 3.29.


Revance Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Revance Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Cyclically Adjusted Book per Share Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.90 4.91

Revance Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 4.91 4.89 4.74 4.32

Competitive Comparison of Revance Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Revance Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Revance Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Revance Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.4/133.0289*133.0289
=-1.400

Current CPI (Sep. 2024) = 133.0289.

Revance Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 6.016 99.070 8.078
201503 6.308 99.621 8.423
201506 5.538 100.684 7.317
201509 5.217 100.392 6.913
201512 8.219 99.792 10.956
201603 7.471 100.470 9.892
201606 6.743 101.688 8.821
201609 6.272 101.861 8.191
201612 5.859 101.863 7.652
201703 5.545 102.862 7.171
201706 4.665 103.349 6.005
201709 3.853 104.136 4.922
201712 6.221 104.011 7.957
201803 5.223 105.290 6.599
201806 4.866 106.317 6.089
201809 4.219 106.507 5.270
201812 3.462 105.998 4.345
201903 4.447 107.251 5.516
201906 3.783 108.070 4.657
201909 3.114 108.329 3.824
201912 3.875 108.420 4.755
202003 4.894 108.902 5.978
202006 3.962 108.767 4.846
202009 4.754 109.815 5.759
202012 4.447 109.897 5.383
202103 2.873 111.754 3.420
202106 2.153 114.631 2.499
202109 1.422 115.734 1.634
202112 0.847 117.630 0.958
202203 0.323 121.301 0.354
202206 -0.034 125.017 -0.036
202209 1.788 125.227 1.899
202212 0.144 125.222 0.153
202303 -0.297 127.348 -0.310
202306 0.281 128.729 0.290
202309 -1.133 129.860 -1.161
202312 -1.580 129.419 -1.624
202403 -0.869 131.776 -0.877
202406 -1.150 132.554 -1.154
202409 -1.400 133.029 -1.400

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Revance Therapeutics  (STU:RTI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Revance Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.44/4.32
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Revance Therapeutics was 6.89. The lowest was 0.48. And the median was 3.29.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Revance Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines